exemestane: Clinical Trials

139 trials of exemestane, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

66 completed, 17 unknown, 16 terminated, 13 recruiting. 139 Phase 2, 13 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2139Completed 66, Unknown 17, Terminated 16, Recruiting 13, Active not recruiting 10, Not yet recruiting 9, Withdrawn 8
Phase 113Terminated 5, Completed 4, Recruiting 2, Not yet recruiting 1, Unknown 1
Phase 33Unknown 2, Terminated 1

Follow exemestane: new trials by email Literature Review of exemestane trials Research Report on exemestane

Trials (filtered) newest first · largest first

All 139 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer
Phase 2Not yet recruitingUniversity of California, San Diego1502027-07-012026-07-27
A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer
Abemaciclib, Tersolisib, Letrozole - Breast Neoplasms
Phase 2Not yet recruitingEli Lilly and Company1202026-12-012026-11-13
KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer
KC1086, Fulvestrant, Everolimus (10 mg QD) - HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Phase 2Not yet recruitingBeijing Konruns Pharmaceutical Co., Ltd.1682026-11-012026-11-16
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy
Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer
Phase 2Not yet recruitingHebei Medical University Fourth Hospital402026-10-012026-08-26
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
Exemestane, Tamoxifen - Breast Cancer, Ductal Carcinoma
Phase 2Not yet recruitingDana-Farber Cancer Institute1402026-09-092026-03-30
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder
Phase 1 / Phase 2Not yet recruitingUniversity of Illinois at Chicago1002026-09-012026-08-24
Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)
elacestrant and exemestane - Breast Cancer
Phase 2RecruitingEuropean Institute of Oncology262026-05-112026-05-14
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen - Breast Diseases, Breast Neoplasms
Phase 2RecruitingFujian Cancer Hospital20002026-01-212026-05-12
An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
Trastuzumab and Pertuzumab Combination with Palbociclib and Exemestane - Breast Cancer
Phase 2Not yet recruitingAnhui Provincial Cancer Hospital902025-12-202025-12-23
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
Tamoxifen 10 MG, Exemestane 25 MG - Breast Cancer
Phase 2RecruitingAndrea DeCensi1402025-10-012025-11-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Trastuzumab rezetecan, Pyrotinib, Dalpiciclib - HER2-positive Breast Cancer
Phase 2Not yet recruitingFudan University2882025-09-102025-09-18
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) - Early Breast Cancer, Adjuvant Therapy
Phase 2Not yet recruitingFujian Cancer Hospital2002025-09-012025-08-03
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm
Phase 2RecruitingMerck Sharp & Dohme LLC2502025-08-112026-10-06
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
Phase 2TerminatedOHSU Knight Cancer Institute62025-06-242026-04-28
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Belzutifan, Fulvestrant, Everolimus - Metastatic Breast Cancer
Phase 2Active not recruitingMerck Sharp & Dohme LLC1202024-11-272026-08-28
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Abemaciclib, Anastrozole, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Phase 2RecruitingUniversity of Washington602024-07-222026-09-24
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Letrozole, Anastrozole, Exemestane - HR+/HER2- Advanced/Metastatic Breast Cancer
Phase 2Active not recruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.782024-02-292025-05-04
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Tamoxifen, Exemestane, Letrozole - Ductal Carcinoma in Situ
Phase 2RecruitingQuantumLeap Healthcare Collaborative4002024-02-172026-10-26
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
Biospecimen Collection, Chest Radiography, Computed Tomography - Adult Ovarian Granulosa Cell Tumor
Phase 2CompletedNational Cancer Institute (NCI)172024-02-082026-11-03
First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer
Ribociclib - Advanced Breast Cancer
Phase 2CompletedThe First Affiliated Hospital with Nanjing Medical University742024-01-092026-08-05

Showing 20 of 139. Sign in to see all of them.

Conditions studied

Breast Neoplasms (112)  ·  Neoplasm Metastasis (8)  ·  Breast Diseases (4)  ·  Endometrial Neoplasms (3)  ·  Ovarian Neoplasms (3)  ·  Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Breast Carcinoma In Situ (1)  ·  Bulbo-Spinal Atrophy, X-Linked (1)  ·  Carcinoma, Ductal (1)  ·  Carcinoma, Intraductal, Noninfiltrating (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Endometrial Hyperplasia (1)  ·  Endometrial Stromal Tumors (1)  ·  Granulosa cell tumor of the ovary (1)

Sponsors

Pfizer (9)  ·  Dana-Farber Cancer Institute (5)  ·  Novartis Pharmaceuticals (5)  ·  Merck Sharp & Dohme LLC (4)  ·  Eli Lilly and Company (3)  ·  National Cancer Institute (NCI) (3)  ·  Chinese Academy of Medical Sciences (2)  ·  City of Hope Medical Center (2)  ·  Emory University (2)  ·  Fujian Cancer Hospital (2)  ·  Georgetown University (2)  ·  Mayo Clinic (2)  ·  NYU Langone Health (2)  ·  Ohio State University Comprehensive Cancer Center (2)  ·  Spanish Breast Cancer Research Group (2)

Countries

United States (76)  ·  China (20)  ·  Spain (19)  ·  United Kingdom (18)  ·  Belgium (15)  ·  France (14)  ·  Canada (13)  ·  Italy (13)  ·  Germany (9)  ·  Brazil (8)  ·  South Korea (8)  ·  Argentina (7)  ·  Japan (7)  ·  Australia (6)  ·  Ireland (6)

Top investigators

Erica Mayer, MD, MPH (2)  ·  Hannah Linden (2)  ·  Jonas Bergh, Professor (2)  ·  Oana Danciu, MD (2)  ·  Adrian L. Harris, MD (1)  ·  Adrienne C Waks, MD (1)  ·  Alessandro Morabito, M.D. (1)  ·  Andrea Gombos, MD (1)  ·  Andrea U De Censi, MD (1)

Results publications

PMID 21717449, PMID 22444722, PMID 22674146, PMID 23053638, PMID 23650416, PMID 24498853, PMID 24674873, PMID 25101563, PMID 26504153, PMID 26758879, PMID 26786263, PMID 27903675, PMID 28314691, PMID 28324268, PMID 28681171, PMID 29124456, PMID 29566104, PMID 29608913, PMID 29862411, PMID 29893790, PMID 29899867, PMID 31250880, PMID 31434793, PMID 31668850, PMID 32043762, PMID 32660609, PMID 33451345, PMID 33761970, PMID 33820779, PMID 34667023, PMID 35223459, PMID 35405087, PMID 36398439, PMID 36410913, PMID 36905771, PMID 36951827, PMID 37166817, PMID 37294342, PMID 37308971, PMID 37348019, PMID 37460683, PMID 37690320, PMID 38123789, PMID 38904918, PMID 39028923, PMID 39110531, PMID 39384801, PMID 39730000, PMID 39978378, PMID 41697438

NIH funding

2014 (3), 2017 (3), 2016 (2), 2023 (2), 2009 (1), 2018 (1), 2019 (1), N01CN00033 (1), N01CN00034 (1), P30CA014520 (1), P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P30CA138292 (1), R21CA277311 (1)